allogeneic anti-CD19 CAR double-negative T cells RJMty19
An off-the-shelf (OTS) cell preparation composed of healthy, donor-derived CD4 and CD8 double-negative T lymphocytes (DNTs) that are transduced with a lentiviral vector expressing a humanized chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, the allogeneic anti-CD19 CAR DNTs RJMty19 specifically targets and binds to tumor cells expressing CD19. This induces selective toxicity in tumor cells that express CD19. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. The DNTs contain a high proportion of stem cell-like memory T cells (Tscm).
| Synonym: | allo-DNT cells RJMty19 allogeneic anti-CD19 CAR DNT cells RJMty19 allogeneic anti-CD19 CAR-engineered double negative T cells RJMty19 allogeneic DNT cells RJMty19 allogeneic DNTs RJMty19 bi-negative T cells RJMty19 CD19-CAR-DNT cells RJMty19 lentiviral vector-transduced anti-CD19-CAR DNT cells RJMty19 |
|---|---|
| Code name: | RJMty 19 RJMty-19 RJMty19 |